Jul 06, 2018 / 12:35
Japan's Taisho Group offers to buy extra 7.06% stake in DHG Pharmaceutical
The deal is expected to cost the Japanese pharmaceutical company VND1.1 trillion (US$47.68 million).
Japan-based Taisho Group has announced its intention to purchase another 7.06% stake of DHG Pharmaceutical JSC (DHG) in a public offer at a price of VND120,000 (US$5.20) apiece, 20% higher than the market price of VND99,900 (US$4.34) at the close on July 4, DHG said in a filing to the Ho Chi Minh City Stock Exchange (HOSE).
At such price, Taisho Group is expected to spend nearly VND1.1 trillion (US$47.68 million) in exchange for 9.2 million shares of Hau Giang Pharmaceutical.
Once the deal is completed, Taisho Group will increase its holding in the Vietnamese firm to 32% or over 41.83 million shares. The proposed time to realize this public offer is within 30 to 60 days after receiving the written approval from the State Securities Commission of Vietnam (SSC) on the public offer.
The Japanese group in early June spent VND85.5 billion (US$3.71 million) for 650,000 shares of DHG, raising its holding in the Vietnamese medicine producer to 24.94%.
Over the past month, DHG shares have lost 13% in value. However, since its listing, the company's share value increased a whooping of 459% to VND99,900 (US$4.34) per share at the close on July 4.
The shares then increased by 5.31% to VND105,200 (US$4.57) apiece at the close of July 5.
On July 4, DHG Pharmaceutical's foreign ownership limit was removed, as a result, the company adjusted its strategic targets for period 2018 - 2020 to a minimum increase of revenue at 13% and pre-tax profit of at least 7%.
Illustration photo.
|
Once the deal is completed, Taisho Group will increase its holding in the Vietnamese firm to 32% or over 41.83 million shares. The proposed time to realize this public offer is within 30 to 60 days after receiving the written approval from the State Securities Commission of Vietnam (SSC) on the public offer.
The Japanese group in early June spent VND85.5 billion (US$3.71 million) for 650,000 shares of DHG, raising its holding in the Vietnamese medicine producer to 24.94%.
Over the past month, DHG shares have lost 13% in value. However, since its listing, the company's share value increased a whooping of 459% to VND99,900 (US$4.34) per share at the close on July 4.
The shares then increased by 5.31% to VND105,200 (US$4.57) apiece at the close of July 5.
On July 4, DHG Pharmaceutical's foreign ownership limit was removed, as a result, the company adjusted its strategic targets for period 2018 - 2020 to a minimum increase of revenue at 13% and pre-tax profit of at least 7%.
Other News
- Aircraft manufacturer Embraer seeks comprehensive aviation partnership with Vietnam
- Better links with FDI firms to support Hanoi businesses
- Vietnam calls for more US investment in innovation, hi-tech
- Vietnamese leader urges Boeing to build production facility in Vietnam
- Foreign capital pouring into Vietnam's real estate market
- Vietnam news in brief - August 24
- Growing number of FDI firms moving to Vietnam
- Vietnam Gov’t committed to facilitating Adani Group’s US$2-billion port project
- Vietnam Railway proposes US$87 million for Hanoi–Dong Dang railway upgrade
- Vietnam’s North-South high-speed railway to be designed for 350km/h
Trending
-
Vietnam’s future path hinges on ASEAN robust development: Party Chief
-
Vietnam news in brief - November 24
-
Are Vietnamese people living healthier lives?
-
Finding ways to unlock Hanoi's suburban tourism potential
-
Hang Ma Street gears up for festive season
-
A Hanoi artisan turns straw into appealing tourism product
-
“Look! It’s Amadeus Vu Tan Dan” workshop - an artistic journey for kids
-
Vietnam news in brief - November 15
-
Experiencing ingenious spaces at the Hanoi Creative Design Festival 2024